Kaiku Health along with Novartis have developed a digital patient monitoring and management for melanoma patients. Melanoma is less common than other types of skin cancer, but it can more easily spread to other parts of the body. “We are excited to collaborate with Novartis to develop together more personalized symptom management and patient support for melanoma patients," says Lauri Sippola, CEO of Kaiku Health. "The introduction of several oral targeted therapies has resulted in growing need for improved ways for monitoring patients remotely during their treatments, and we are excited to work closely with Novartis and several leading cancer centers in further improving the digital patient monitoring and management of melanoma patients."
About half of melanoma patients have BRAF V600-positive melanoma and may be eligible for BRAF and MEK inhibitor combination therapy to treat the cancer. The treatment is an oral targeted therapy that patients typically take outside the cancer centers. The companies are aiming to improve the remote monitoring and supporting patients receiving BRAF/MEK combination therapies for melanoma. The module is designed to track symptoms and provide personalized symptom self-management guidance and patient education. The platform will automatically notify the care team if patients’ symptoms get worse during the treatment course.
Patients can use Kaiku Health on their smartphones and tablets or the web browser-based application on their computers. They are planning to pilot the co-created module in cancer centers located in Germany, Netherlands, Switzerland, and Italy in May 2021.